Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PDE6D | O43924 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946913 | 0.93 | LMNA (0.49) | GLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4942573 | 0.93 | LMNA (0.48) | GLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4943430 | 0.90 | LMNA (0.49) | GLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4946150 | 0.88 | LMNA (0.51) | LMNAALDH1A1SSTR4SSTR3MAPK1 | |
| SCHEMBL4944067 | 0.88 | MAPT (0.49) | GLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4943001 | 0.88 | ALDH1A1 (0.49) | LMNAMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL4946394 | 0.87 | MAPT (0.49) | GLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4942008 | 0.87 | HPGD (0.54) | LMNAKMT2AALDH1A1NPSR1SSTR4 | |
| SCHEMBL4945565 | 0.87 | HPGD (0.54) | GLACYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4942086 | 0.86 | MEN1 (0.54) | GLACYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | claimed |
| EP-1458381-B1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-30 | — | — | EP | claimed |
| US-20050187275-A1 | Triazoles as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-25 | — | — | US | claimed |
| EP-1458381-A1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | Applied Research Systems ARS Holding N.V. (AN) | 2004-09-22 | — | — | EP | claimed |
| WO-2003053437-A1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-07-03 | — | — | WO | claimed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-20050187275-A1 | Triazoles as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-25 | — | — | US | disclosed |
| WO-2003053437-A1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187275-A1 | Triazoles as oxytocin antagonists | OXTR, AVPR2, AVPR1B | GLA 4817/4885CYP3A4 2195/4885CYP2D6 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.